Chardan Capital Markets Starts Cognition Therapeutics (CGTX) at Buy

Chardan Capital Markets analyst Daniil Gataulin initiates coverage on Cognition Therapeutics (NASDAQ: CGTX) with a Buy rating and a price target of $11.00.

The analyst comments "We initiate coverage on Cognition Therapeutics with a Buy rating and $11 PT based on the potential of the company's lead asset CT1812 in Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB). CT1812 is a highly brain-penetrant, orally administered small molecule modulator of a sigma-2 receptor complex that acts to displace toxic beta-amyloid (Aß) and alpha synuclein (αSyn) oligomers implicated in the pathogenesis of AD and DLB, respectively. A series of clinical and preclinical studies provide a strong validation for CT1812 mechanism of action in AD, which is distinct from the approved anti-Aß monoclonal antibody approaches, and could provide an added benefit if used in combination with those therapies."

For an analyst ratings summary and ratings history on Cognition Therapeutics click here. For more ratings news on Cognition Therapeutics click here.

Shares of Cognition Therapeutics closed at $1.90 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat